<DOC>
	<DOCNO>NCT02930655</DOCNO>
	<brief_summary>The primary purpose study assess safety tolerability lucerastat adult Fabry Disease receive Enzyme Replacement Therapy ( ERT ) . The secondary objective investigate effect lucerastat plasma urine level biomarkers , assess effect renal cardiac function determine pharmacokinetic profile lucerastat steady-state .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability Lucerastat Subjects With Fabry Disease</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Signed informed consent form Male female adult subject diagnosis Fabry Disease ( FD ) base historical assessment ( residual Î±GAL A activity level lower limit normal male presence galactosidase alpha mutation female ) history clinical symptom FD On ERT least 24 month without change dose within last 6 month prior screen Severe renal function impairment Severe residual neurologic deficit Clinically significant unstable cardiac disease Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Fabry disease</keyword>
	<keyword>lucerastat</keyword>
</DOC>